Replimune (REPL)

The company’s approach is based on the idea that local tumor destruction can help expose cancer antigens and turn the tumor microenvironment into a stronger trigger for systemic anti-tumor immunity. Replimune adds selected therapeutic payloads to its viral candidates to enhance immunogenic cell death and immune activation. This places the company within the wider field of cancer immunotherapy, alongside checkpoint inhibitors, cell therapies, targeted antibodies, and other technologies intended to improve the immune system’s ability to recognise and attack tumors.

Replimune’s pipeline includes RP1, RP2, and RP3. These investigational programs are aimed at solid tumors and are being evaluated in clinical development, including in settings where combination strategies with other immunotherapies may be relevant. As a clinical-stage company, Replimune’s value is driven less by current product sales and more by trial outcomes, regulatory progress, manufacturing capability, intellectual property, and the potential commercial opportunity for its candidates if approved.

The company operates in both the United States and the United Kingdom, with the US representing the larger share of its reported revenue. For investors, Replimune offers exposure to a specialized segment of oncology drug development, but it also carries the typical risks of biotech investing, including clinical uncertainty, funding needs, regulatory review, and competition from established and emerging cancer therapies.